$358 Million is the total value of Abingworth LLP's 16 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | New | Vaxcyte | $131,523,000 | – | 4,168,718 | +100.0% | 36.77% | – |
| PSNL | Personalis | $70,623,000 | +62.0% | 5,449,294 | 0.0% | 19.75% | -31.8% | |
| PHAT | Phathom | $39,367,000 | +27.7% | 1,203,135 | 0.0% | 11.01% | -46.2% | |
| CRSP | Crisprnamen akt | $38,062,000 | +73.4% | 519,198 | 0.0% | 10.64% | -27.0% | |
| SLNO | Buy | Soleno | $22,769,000 | +45.2% | 10,302,602 | +47.8% | 6.37% | -38.9% |
| XCUR | Exicure | $16,954,000 | +66.4% | 6,977,000 | 0.0% | 4.74% | -29.9% | |
| SRRA | Sierra Oncology | $10,536,000 | +22.7% | 876,541 | 0.0% | 2.95% | -48.4% | |
| SIEN | Sientra | $9,229,000 | +96.9% | 2,390,843 | 0.0% | 2.58% | -17.1% | |
| PRTK | Paratek | $5,424,000 | +67.5% | 1,041,131 | 0.0% | 1.52% | -29.4% | |
| VRNA | Veronasponds adr | $4,221,000 | +13.6% | 901,943 | 0.0% | 1.18% | -52.2% | |
| TARA | New | Protara | $3,001,000 | – | 53,612 | +100.0% | 0.84% | – |
| MTEM | Molecular Templates | $2,758,000 | +4.4% | 200,000 | 0.0% | 0.77% | -56.1% | |
| AGLE | Aeglea | $2,221,000 | +101.2% | 240,500 | 0.0% | 0.62% | -15.3% | |
| OBSV | Obseva | $517,000 | +146.2% | 87,999 | 0.0% | 0.14% | +4.3% | |
| CBAY | Cymabay | $456,000 | +138.7% | 131,036 | 0.0% | 0.13% | 0.0% | |
| HSGX | Ocugen | $2,000 | 0.0% | 7,111 | 0.0% | 0.00% | 0.0% | |
| CHMA | Exit | Chiasma | $0 | – | -370,671 | -100.0% | -0.89% | – |
| TARA | Exit | Artara | $0 | – | -113,919 | -100.0% | -1.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.